Phenotypes Associated with This Genotype

Genotype
MGI:5644542

• Allelic Composition: Atm^tm1Pmc/Atm^tm1Pmc
• Genetic Background: B6.Cg-Atm^tm1Pmc

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

decreased circulating leptin level ( J:222034 )

impaired glucose tolerance ( J:222034 )

• mice exhibit glucose intolerance

• rosiglitazone treatment or metformin treatment improve glucose intolerance in mutants

insulin resistance ( J:222034 )

decreased circulating adiponectin level ( J:222034 )

• reduction in serum adiponectin levels

• rosiglitazone, but not metformin, treatment increases serum adiponectin levels in mutants

adipose tissue

decreased subcutaneous adipose tissue amount ( J:222034 )

abnormal adipose tissue distribution ( J:222034 )

• decrease in the amount of intrascapular and subcutaneous fat tissue and an increase in the amount of visceral fat tissue

abnormal fat cell differentiation ( J:222034 )

• mouse embryonic fibroblasts (MEFs) fail to differentiate into adipocytes in vitro

• rosiglitazone treatment restores adipocyte differentiation in MEFs

behavior/neurological

increased food intake ( J:222034 )

cellular

abnormal fat cell differentiation ( J:222034 )

• mouse embryonic fibroblasts (MEFs) fail to differentiate into adipocytes in vitro

• rosiglitazone treatment restores adipocyte differentiation in MEFs

abnormal cell cycle ( J:222034 )

• MEFs re-enter the cell cycle normally after differentiation stimulation, but the cell cycle is not arrested at 8 days after differentiation stimulation as seen in wild-type MEFs undergoing terminal differentiation

integument

decreased subcutaneous adipose tissue amount ( J:222034 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
ataxia telangiectasia		DOID:12704	OMIM:208900	J:222034